Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bempedoic Acid Added to PCSK9 Inhibitor Therapy in Hypercholesterolemia
NCT03193047Phase 2Completed
- Sponsor
- Esperion Therapeutics
- Start
- Apr 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypercholesterolemia comparing Bempedoic Acid + Evolocumab with Placebo + Evolocumab (2 arms). Primary endpoint: Percent Change From Baseline in Low-density Lipoprotein Cholesterol at Month 2. Started Apr 2017; status: completed.
02
Drugs
bempedoic acid
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT03193047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03193047.